HALO: Record revenue, robust pipeline, and new platforms position for sustained royalty growth
Expansion into China and rapid AI adoption are driving operational gains and new partnerships. Record Q2 revenue and a diversified royalty base support strong long-term guidance, while new platforms like Hypercon and Surf Bio are set to expand future royalty streams.Based on Halozyme Therapeutics…